Table 1.

Baseline Characteristics

	Eyes treated with 0.2 µg/day FAc intravitreal implant (n=15 patients/19 eyes)
Age (years), mean±SD	64.7±14.08
Males, %	66.7
Race, %
Caucasian	26.7
Black/African American	40.0
Asian/Middle East Indian	13.3
Latino	13.3
Native Hawaiian	6.7
Type 2 diabetes, %	93.3
Diagnosis (years) before FAc, mean
DME (n=19 eyes)	2.90±2.45
HbA1C, mean (%)	7.07
Initial lens status—Phakic %/Pseudophakic % (n=19 eyes)	42.1/57.9
Follow-up time (days)—Prior to FAc/After FAc administration	872.7±601.8/399.3±222.91

FAc, fluocinolone acetonide.